GPT possesses a vast collection of immune-deficient strains and target humanized strains on both C57BL/6 and BALB/c backgrounds, coupled with an extensive resource of tumor cell lines. We offer tumor efficacy services using a variety of wild-type and humanized cells for both subcutaneous and orthotopic tumor studies. Furthermore, we supply a significant number of mouse models with commonly used human cell lines for subcutaneous tumor xenograft studies. By leveraging our comprehensive tumor induction data and robust experimental systems, we ensure that our customers receive stable and reliable oncology mouse models.
Service Contents
6 Types of Tumor Bearing Mouse Models
Serial Number | Strain Number | Strain Name |
Strain 1 | T064538 | BALB/c-Nude+CDX |
Strain 2 | T064540 | NCG+CDX |
Strain 3 | T064541 | BALB/c(background)+Syngeneic Cell Lines |
Strain 4 | T064543 | C57BL/6(background)+Syngeneic Cell Lines |
Strain 5 | T064544 | BALB/c(background)+Immune Checkpoint Single Target + Syngeneic Cell Lines |
Strain 6 | T064545 | C57BL/6(background)+Immune Checkpoint Single Target + Syngeneic Cell Lines |
Cancer Cell Lines
Cell origin | Type | Cell Lines |
Syngeneic Cell Lines | Lymphoma | A20, J558 |
Melanoma | B16F0, B16F1, B16F10 | |
Lung | LLC1, KLN 205 | |
Liver | H22 | |
Gastric Carcinoma | RENCA | |
Pancreas | PAN02 | |
Colorectal | CT26.WT, MC38 | |
Breast | 4T1, EMT6 | |
CDX | Leukemia | HL-60, Jurkat, K-562, MOLT-4, MV-4-11, NALM-6, SUP-B15, THP-1, OCI-AML-3 |
Lymphoma | U-937, JeKo-1, Daudi, Ramos, Raji, SU-DHL-10, U-2932 | |
Multiple Myeloma | MM.1S, NCI-H929, MM.1R, RPMI 8226 | |
Melanoma | A-375, COLO 829, SK-MEL-28, SK-MEL-5 | |
Cutaneous Squamous Cell | A-431 | |
Sarcoma | HT-1080, SJSA-1 | |
Glioma | U-87 MG, U-251 MG | |
Neuroblastoma | SK-N-BE(2) | |
Submandibular Gland Squamous Cell | A-253 | |
Squamous Cell | CAL 27 | |
Squamous Cell | FaDu | |
Esophageal Cancer | OE33 | |
Esophageal Squamous Cell | KYSE-150 | |
Lung | A549, DMS 53, HCC827, NCI-H1703, NCI-H1975, NCI-H2122, NCI-H226, NCI-H292, NCI-H358, NCI-H446, NCI-H460, NCI-H82, NCI-H441, NCI-H69, NCI-H1650, SHP-77, NCI-H1299 | |
Liver | Huh-7, Hep G2 | |
Kidney | ACHN, 786-O | |
Pancreatic | AsPC-1, BxPC-3, Capan-1, CFPAC-1, MIA PaCa-2, PANC-1, SW 1990 | |
Stomach | Hs746T, MKN45, NCI-N87, SNU-16, NUGC-4 | |
Duodenal | HuTu 80 | |
Colon | LS1034, SW948, SW480, SW620, COLO 320 | |
Colorectal | COLO 205, HCT116, HT-29, HT-55, LoVo, LS174T, RKO, SW48 | |
Bladder | RT112/84 | |
Breast | BT-474, HCC1937, HCC1954, HCC1569, JIMT-1, MCF7, MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468, HCC70, T-47D | |
Ovarian | TOV-21G, SK-OV-3, OVCAR-3 | |
Ovarian Teratoma | PA-1 | |
Ovarian Clear Cell | ES-2 | |
Endometrial | HEC-1-A | |
Prostate | LNCaP C4-2B, LNCaP Clone FGC, 22Rv1 |
Case
Cell Line 1 | Inoculation Concentration | Background | Site | Grouping Time | Grouping Volume (mm³) |
MDA-MB-231 | 5×106/100 μL/Piece (1:1Matrigel) | NCG | 3# | D10-D12 | 80-100 |
At GPT, the subcutaneous tumor implantation model is straightforward to operate, with a high success rate and easily accessible tumor volume measurements. Initially, tumors exhibit slow growth, which later transitions to exponential growth.
Figure 1. NCG+ MDA-MB-231
Cell Line 2 | Inoculation Concentration | Background | Site | Grouping Time | Grouping Volume (mm³) |
LS174T | 5×106/100 μL/site (1:1 Matrigel) | Nude | 3# | D5-D7 | 80-120 |
The LS174T model shows rapid tumor growth in its early stages and has a short overall experimental cycle, making it ideal for high-throughput drug screening. However, in the later stages, the tumors exhibit exponential growth and are susceptible to ulceration and scabbing. Handling the mice frequently might result in severe tumor ulceration and an increased risk of tumor nibbling, necessitating housing in individual cages.
Figure 2. BALB/c-Nude+LS174T
Cell Line 3 | Inoculation Concentration | Background | Site | Grouping Time | Grouping Volume (mm³) |
A-375 | 5×106/100 μL/piece (1:1 Matrigel) | NCG | 3# | D6-D8 | 80-120 |
A-375 human melanoma cells were inoculated into NCG mice via subcutaneous injection, and tumor volumes were measured at different time points. The cell inoculation volume was 5×106 cells per mouse, with or without the addition of matrix gel for comparison. The data are presented as Mean±SEM. The results demonstrate that an effective tumor model of human malignant melanoma can be established in NCG mice, with more uniform tumor growth observed when matrix gel is added. Similar to the previous models, the A-375 tumor exhibits slow initial growth, followed by exponential growth, with slight scabbing observed on the tumor surface and a low ulceration rate.
Figure 3. NCG + A-375
Cell Line 4 | Inoculation Concentration | Background | Site | Grouping Time | Grouping Volume (mm³) |
MC38 | 1×106/100 μL/piece | C57BL/6 | 3# | D7-D9 | 90-100 |
The MC38 model exhibits rapid growth in the later stages. Similar to the previous models, frequent handling of the mice may lead to severe tumor ulceration, requiring single-cage housing to minimize experimental errors.
Figure 4. C57BL/6 + MC38
Cell Line 5 | Inoculation Concentration | Background Mouse | Site | Grouping Time | Grouping Volume(mm³) |
CT26.WT | 1×106/100 μL/piece | BABL/c | 1# | D9-D11 | 70-90 |
The CT26.WT model exhibits rapid early-stage growth and a short overall experimental cycle, making it suitable for high-throughput drug screening. However, in the later stages, the tumors are prone to ulceration and scabbing. Frequent handling of the mice may lead to severe tumor ulceration and a risk of tumor nibbling, thus requiring single-cage housing.
Figure 5. CT26.WT+BALB/c
GPT Advantages
300+ cell lines are accompanied by tumor growth validation data..
Reliable, swift, and consistent mouse transportation system ensures accurate tumor volume delivery.
Stable experimental systems for both cell culture recovery and tumor implantation.
Rich resources of tumor cell lines.
Extensive experience in project experimentationadhering to regulatory requirements for new drug applications.
Clear risk alerts and compensation guidelines, effectively safeguard customer rights and interests.